International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed/refractory acute lymphoblastic leukemia

被引:160
|
作者
Goekbuget, Nicola [1 ]
Dombret, Herve [2 ]
Ribera, Jose-Maria [3 ]
Fielding, Adele K. [4 ]
Advani, Anjali [5 ]
Bassan, Renato [6 ]
Chia, Victoria [7 ]
Doubek, Michael [8 ]
Giebel, Sebastian [9 ,10 ]
Hoelzer, Dieter [1 ]
Ifrah, Norbert [11 ]
Katz, Aaron [7 ]
Kelsh, Michael [7 ]
Martinelli, Giovanni [12 ]
Morgades, Mireia [3 ]
O'Brien, Susan [13 ]
Rowe, Jacob M. [14 ]
Stieglmaier, Julia [15 ]
Wadleigh, Martha [16 ]
Kantarjian, Hagop [13 ]
机构
[1] Goethe Univ, Univ Hosp, Frankfurt, Germany
[2] Hop St Louis, Paris, France
[3] Hosp Badalona Germans Trias & Pujol, ICO, Jose Carreras Res Inst, Barcelona, Spain
[4] UCL, Inst Canc, London, England
[5] Cleveland Clin, Cleveland, OH 44106 USA
[6] Osped Angelo, UOC Ematol, Mestre Venezia, Italy
[7] Amgen Inc, Ctr Observat Res, Thousand Oaks, CA USA
[8] Univ Hosp, Brno, Czech Republic
[9] Maria Sklodowska Curie Mem Canc Ctr, Gliwice, Poland
[10] Inst Oncol, Gliwice, Poland
[11] Ctr Hosp Univ, Angers, France
[12] Ist Seragnoli, Policlin St Orsola, Bologna, Italy
[13] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[14] Rambam Med Ctr, Haifa, Israel
[15] Amgen Inc, Clin Dev, Munich, Germany
[16] Dana Farber Canc Inst, Boston, MA 02115 USA
关键词
ACUTE LYMPHOCYTIC-LEUKEMIA; SALVAGE THERAPY; PHASE-II; RELAPSE; REMISSIONS; BLINATUMOMAB; PROGNOSIS; TRIAL;
D O I
10.3324/haematol.2016.144311
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Adults with relapsed/refractory acute lymphoblastic leukemia have an unfavourable prognosis, which is influenced by disease and patient characteristics. To further evaluate these characteristics, a retrospective analysis of 1,706 adult patients with Ph-negative relapsed/refractory B-precursor acute lymphoblastic leukemia diagnosed between 1990-2013 was conducted using data reflecting the standard of care from 11 study groups and large centers in Europe and the United States. Outcomes included complete remission, overall survival, and realization of stem cell transplantation after salvage treatment. The overall complete remission rate after first salvage was 40%, ranging from 35%-41% across disease status categories (primary refractory, relapsed with or without prior transplant), and was lower after second (21%) and third or greater (11%) salvage. The overall complete remission rate was higher for patients diagnosed from 2005 onward (45%, 95% CI: 39%-50%). One-and three-year survival rates after first, second, and third or greater salvage were 26% and 11%, 18% and 6%, and 15% and 4%, respectively, and rates were 2%-5% higher among patients diagnosed from 2005. Prognostic factors included younger age, longer duration of first remission, and lower white blood cell counts at primary diagnosis. This large dataset can provide detailed reference outcomes for patients with relapsed/refractory Ph-negative B-precursor acute lymphoblastic leukemia. clinicaltrials.gov identifier: 02003612
引用
收藏
页码:1524 / 1533
页数:10
相关论文
共 50 条
  • [1] Minimal residual disease level predicts outcome in adults with Ph-negative B-precursor acute lymphoblastic leukemia
    Goekbuget, Nicola
    Dombret, Nerve
    Giebel, Sebastian
    Bruggemann, Monika
    Doubek, Michael
    Foa, Robin
    Hoelzer, Dieter
    Kim, Christopher
    Martinelli, Giovanni
    Parovichnikova, Elena
    Rambaldi, Alessandro
    Ribera, Josep-Maria
    Schoonen, Marieke
    Stieglmaier, Julia M.
    Zugmaier, Gerhard
    Bassan, Renato
    HEMATOLOGY, 2019, 24 (01) : 337 - 348
  • [2] Blinatumomab consolidation and maintenance therapy in adults with relapsed/refractory B-precursor acute lymphoblastic leukemia
    Rambaldi, Alessandro
    Huguet, Francoise
    Zak, Pavel
    Cannell, Paul
    Tran, Qui
    Franklin, Janet
    Topp, Max S.
    BLOOD ADVANCES, 2020, 4 (07) : 1518 - 1525
  • [3] Liposomal vincristine for relapsed or refractory Ph-negative acute lymphoblastic leukemia: a review of literature
    Pathak, Priyanka
    Hess, Rosemary
    Weiss, Mark A.
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2014, 5 (01) : 18 - 24
  • [4] Impact of cytogenetic abnormalities in adults with Ph-negative B-cell precursor acute lymphoblastic leukemia
    Lafage-Pochitaloff, Marina
    Baranger, Laurence
    Hunault, Mathilde
    Cuccuini, Wendy
    Lefebvre, Christine
    Bidet, Audrey
    Tigaud, Isabelle
    Eclache, Virginie
    Delabesse, Eric
    Bilhou-Nabera, Chrystele
    Terre, Christine
    Chapiro, Elise
    Gachard, Nathalie
    Mozziconacci, Marie-Joelle
    Ameye, Genevieve
    Porter, Sarah
    Grardel, Nathalie
    Bene, Marie C.
    Chalandon, Yves
    Graux, Carlos
    Huguet, Francoise
    Lheritier, Veronique
    Ifrah, Norbert
    Dombret, Herve
    BLOOD, 2017, 130 (16) : 1832 - 1844
  • [5] Immunopharmacodynamic response to blinatumomab in patients with relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL).
    Schub, Andrea
    Naegele, Virginie
    Zugmaier, Gerhard
    Brandl, Christian
    Hijazi, Youssef
    Topp, Max S.
    Kufer, Peter
    Wolf, Andreas
    Klinger, Matthias
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [6] Blinatumomab versus historical standard therapy in pediatric patients with relapsed/refractory Ph-negative B-cell precursor acute lymphoblastic leukemia
    Franco Locatelli
    James A. Whitlock
    Christina Peters
    Christiane Chen-Santel
    Victoria Chia
    Robyn M. Dennis
    Kenneth M. Heym
    Aaron J. Katz
    Michael A. Kelsh
    Richard Sposto
    Huakang Tu
    Catherine A. Tuglus
    Anupam Verma
    Luciana Vinti
    Jennifer J. Wilkes
    Nathalya Zubarovskaja
    Gerhard Zugmaier
    Arend von Stackelberg
    Weili Sun
    Leukemia, 2020, 34 : 2473 - 2478
  • [7] Blinatumomab versus historical standard therapy in pediatric patients with relapsed/refractory Ph-negative B-cell precursor acute lymphoblastic leukemia
    Locatelli, Franco
    Whitlock, James A.
    Peters, Christina
    Chen-Santel, Christiane
    Chia, Victoria
    Dennis, Robyn M.
    Heym, Kenneth M.
    Katz, Aaron J.
    Kelsh, Michael A.
    Sposto, Richard
    Tu, Huakang
    Tuglus, Catherine A.
    Verma, Anupam
    Vinti, Luciana
    Wilkes, Jennifer J.
    Zubarovskaja, Nathalya
    Zugmaier, Gerhard
    von Stackelberg, Arend
    Sun, Weili
    LEUKEMIA, 2020, 34 (09) : 2473 - 2478
  • [8] Blinatumomab retreatment after relapse in patients with relapsed/refractory B-precursor acute lymphoblastic leukemia
    Topp, M. S.
    Stelljes, M.
    Zugmaier, G.
    Barnette, P.
    Heffner, L. T., Jr.
    Trippett, T.
    Duell, J.
    Bargou, R. C.
    Holland, C.
    Benjamin, J. E.
    Klinger, M.
    Litzow, M. R.
    LEUKEMIA, 2018, 32 (02) : 562 - 565
  • [9] Blinatumomab retreatment after relapse in patients with relapsed/refractory B-precursor acute lymphoblastic leukemia
    M S Topp
    M Stelljes
    G Zugmaier
    P Barnette
    L T Heffner
    T Trippett
    J Duell
    R C Bargou
    C Holland
    J E Benjamin
    M Klinger
    M R Litzow
    Leukemia, 2018, 32 : 562 - 565
  • [10] Immunopharmacodynamic response to blinatumomab in patients with relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL)
    Schub, A.
    Naegele, V
    Zugmaier, G.
    Brandl, C.
    Hijazi, Y.
    Topp, M. S.
    Kufer, P.
    Wolf, A.
    Klinger, M.
    ONKOLOGIE, 2013, 36 : 183 - 183